mRNA And Cell Therapy Demand Will Transform Global Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
06 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$5.00
51.0% undervalued intrinsic discount21 Aug
US$2.45
1Y
-72.1%7D
-4.7%